Radiation Oncology Journal

  • 제35권4호
  • /
  • Pages.368-379
  • /
  • 2017
  • /
  • 2234-1900(pISSN)
  • /
  • 2234-3156(eISSN)
대한방사선종양학회 (The Korean Society for Radiation Oncology)
권호 표지
DOI QR코드

DOI QR Code

Dosimetric advantages and clinical outcomes of simultaneous integrated boost intensity-modulated radiotherapy for anal squamous cell carcinoma

  • Sakanaka, Katsuyuki (Department of Radiation Oncology and Image-Applied Therapy, Graduate School of Medicine, Kyoto University) ;
  • Itasaka, Satoshi (Department of Radiation Oncology and Image-Applied Therapy, Graduate School of Medicine, Kyoto University) ;
  • Ishida, Yuichi (Department of Radiation Oncology and Image-Applied Therapy, Graduate School of Medicine, Kyoto University) ;
  • Fujii, Kota (Department of Radiation Oncology and Image-Applied Therapy, Graduate School of Medicine, Kyoto University) ;
  • Horimatsu, Takahiro (Department of Therapeutic Oncology, Graduate School of Medicine, Kyoto University) ;
  • Mizowaki, Takashi (Department of Radiation Oncology and Image-Applied Therapy, Graduate School of Medicine, Kyoto University) ;
  • Sakai, Yoshiharu (Department of Surgery, Graduate School of Medicine, Kyoto University) ;
  • Hiraoka, Masahiro (Department of Radiation Oncology and Image-Applied Therapy, Graduate School of Medicine, Kyoto University)
  • 투고 : 2017.04.21
  • 심사 : 2017.06.08
  • 발행 : 2017.12.31
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Purpose: The purpose of this study was to explore the dosimetric difference between simultaneous integrated boost intensity-modulated radiotherapy (SIB-IMRT) and three-dimensional conformal radiotherapy (3DCRT), and the clinical outcomes of anal squamous cell carcinoma (ASCC) chemoradiotherapy featuring SIB-IMRT. Materials and Methods: This study included ten patients with ASCC who underwent chemoradiotherapy using SIB-IMRT with 5-fluorouracil and mitomycin C. SIB-IMRT delivered 54 Gy to each primary tumor plus metastatic lymph nodes and 45 Gy to regional lymph nodes, in 30 fractions. Four patients received additional boosts to the primary tumors and metastatic lymph nodes; the median total dose was 54 Gy (range, 54 to 60 Gy). We additionally created 3DCRT plans following the Radiation Therapy Oncology Group 9811 protocol to allow dosimetric comparisons with SIB-IMRT. Locoregional control, overall survival, and toxicity were calculated for the clinical outcome evaluation. Results: Compared to 3DCRT, SIB-IMRT significantly reduced doses to the external genitalia, bladder, and intestine, delivering the doses to target and elective nodal region. At a median follow-up time of 46 months, 3-year locoregional control and overall survival rates were 88.9% and 100%, respectively. Acute toxicities were treated conservatively. All patients completed radiotherapy with brief interruptions (range, 0 to 2 days). No patient experienced ${\geq}grade$ 3 late toxicity during the follow-up period. Conclusion: The dosimetric advantages of SIB-IMRT appeared to reduce the toxicity of chemoradiotherapy for ASCC achieving high locoregional control in the extended period.

키워드

참고문헌

  1. Ajani JA, Winter KA, Gunderson LL, et al. Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial. JAMA 2008;299:1914-21. https://doi.org/10.1001/jama.299.16.1914
  2. James RD, Glynne-Jones R, Meadows HM, et al. Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 $\times$ 2 factorial trial. Lancet Oncol 2013;14:516-24. https://doi.org/10.1016/S1470-2045(13)70086-X
  3. Chen YJ, Liu A, Tsai PT, et al. Organ sparing by conformal avoidance intensity-modulated radiation therapy for anal cancer: dosimetric evaluation of coverage of pelvis and inguinal/femoral nodes. Int J Radiat Oncol Biol Phys 2005;63:274-81. https://doi.org/10.1016/j.ijrobp.2005.05.052
  4. Brooks CJ, Lee YK, Aitken K, Hansen VN, Tait DM, Hawkins MA. Organ-sparing Intensity-modulated radiotherapy for anal cancer using the ACTII schedule: a comparison of conventional and intensity-modulated radiotherapy plans. Clin Oncol (R Coll Radiol) 2013;25:155-61. https://doi.org/10.1016/j.clon.2012.08.008
  5. Kachnic LA, Winter K, Myerson RJ, et al. RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal. Int J Radiat Oncol Biol Phys 2013;86:27-33. https://doi.org/10.1016/j.ijrobp.2012.09.023
  6. Clivio A, Fogliata A, Franzetti-Pellanda A, et al. Volumetricmodulated arc radiotherapy for carcinomas of the anal canal: a treatment planning comparison with fixed field IMRT. Radiother Oncol 2009;92:118-24. https://doi.org/10.1016/j.radonc.2008.12.020
  7. Vieillot S, Azria D, Lemanski C, et al. Plan comparison of volumetric-modulated arc therapy (RapidArc) and conventional intensity-modulated radiation therapy (IMRT) in anal canal cancer. Radiat Oncol 2010;5:92. https://doi.org/10.1186/1748-717X-5-92
  8. Ugurluer G, Ballerini G, Moeckli R, Matzinger O, Bourhis J, Ozsahin M. Helical tomotherapy for the treatment of anal canal cancer: a dosimetric comparison with 3D conformal radiotherapy. Tumori 2015;101:268-72. https://doi.org/10.5301/tj.5000269
  9. Myerson RJ, Garofalo MC, El Naqa I, et al. Elective clinical target volumes for conformal therapy in anorectal cancer: a radiation therapy oncology group consensus panel contouring atlas. Int J Radiat Oncol Biol Phys 2009;74:824-30. https://doi.org/10.1016/j.ijrobp.2008.08.070
  10. Ben-Josef E, Moughan J, Ajani JA, et al. Impact of overall treatment time on survival and local control in patients with anal cancer: a pooled data analysis of Radiation Therapy Oncology Group trials 87-04 and 98-11. J Clin Oncol 2010;28:5061-6. https://doi.org/10.1200/JCO.2010.29.1351
  11. Bazan JG, Luxton G, Mok EC, Koong AC, Chang DT. Normal tissue complication probability modeling of acute hematologic toxicity in patients treated with intensity-modulated radiation therapy for squamous cell carcinoma of the anal canal. Int J Radiat Oncol Biol Phys 2012;84:700-6. https://doi.org/10.1016/j.ijrobp.2011.12.072
  12. Mell LK, Schomas DA, Salama JK, et al. Association between bone marrow dosimetric parameters and acute hematologic toxicity in anal cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys 2008;70:1431-7. https://doi.org/10.1016/j.ijrobp.2007.08.074
  13. Gunderson LL, Winter KA, Ajani JA, et al. Long-term update of US GI intergroup RTOG 98-11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil/mitomycin versus fluorouracil/cisplatin. J Clin Oncol 2012;30:4344-51. https://doi.org/10.1200/JCO.2012.43.8085
  14. Takashima A, Shimada Y, Hamaguchi T, et al. Current therapeutic strategies for anal squamous cell carcinoma in Japan. Int J Clin Oncol 2009;14:416-20. https://doi.org/10.1007/s10147-009-0892-5
  15. Satake H, Yoshino T, Sasaki T, et al. Early clinical outcomes of anal squamous cell carcinoma treated with concurrent chemoradiotherapy with 5-Fluorouracil plus mitomycin C in Japanese patients: experience at a single institution. Jpn J Clin Oncol 2012;42:861-4. https://doi.org/10.1093/jjco/hys093
  16. Joseph K, Nijjar Y, Warkentin H, et al. Prospective phase II study of tomotherapy based chemoradiation treatment for locally advanced anal cancer. Radiother Oncol 2015;117:234-9. https://doi.org/10.1016/j.radonc.2015.08.008
  17. Milano MT, Jani AB, Farrey KJ, Rash C, Heimann R, Chmura SJ. Intensity-modulated radiation therapy (IMRT) in the treatment of anal cancer: toxicity and clinical outcome. Int J Radiat Oncol Biol Phys 2005;63:354-61. https://doi.org/10.1016/j.ijrobp.2005.02.030
  18. Dasgupta T, Rothenstein D, Chou JF, et al. Intensity-modulated radiotherapy vs. conventional radiotherapy in the treatment of anal squamous cell carcinoma: a propensity score analysis. Radiother Oncol 2013;107:189-94. https://doi.org/10.1016/j.radonc.2013.03.012
  19. Call JA, Haddock MG, Quevedo JF, Larson DW, Miller RC. Concurrent chemotherapy and intensity modulated radiation therapy in the treatment of anal cancer: a retrospective review from a large academic center. Pract Radiat Oncol 2013;3:26-31. https://doi.org/10.1016/j.prro.2012.02.005
  20. Pepek JM, Willett CG, Wu QJ, Yoo S, Clough RW, Czito BG. Intensity-modulated radiation therapy for anal malignancies: a preliminary toxicity and disease outcomes analysis. Int J Radiat Oncol Biol Phys 2010;78:1413-9. https://doi.org/10.1016/j.ijrobp.2009.09.046
  21. Kachnic LA, Tsai HK, Coen JJ, et al. Dose-painted intensitymodulated radiation therapy for anal cancer: a multiinstitutional report of acute toxicity and response to therapy. Int J Radiat Oncol Biol Phys 2012;82:153-8. https://doi.org/10.1016/j.ijrobp.2010.09.030
  22. Hodges JC, Beg MS, Das P, Meyer J. Cost-effectiveness analysis of intensity modulated radiation therapy versus 3-dimensional conformal radiation therapy for anal cancer. Int J Radiat Oncol Biol Phys 2014;89:773-83. https://doi.org/10.1016/j.ijrobp.2014.02.012

피인용 문헌

  1. Assessment of the modulation degrees of intensity-modulated radiation therapy plans vol.13, pp.1, 2018, https://doi.org/10.1186/s13014-018-1193-9
  2. Intensity-modulated radiotherapy for cervical esophageal squamous cell carcinoma without hypopharyngeal invasion: dose distribution and clinical outcome vol.60, pp.4, 2019, https://doi.org/10.1093/jrr/rrz019
  3. A Case Report of Locally Advanced Anal Cancer with Solitary Cutaneous Nodular Metastasis in the Ipsilateral Labia Majora Treated with Definitive Chemoradiotherapy vol.12, pp.3, 2017, https://doi.org/10.1159/000503171
  4. A Case Report of a Solitary Pelvic Mass Proven to Be a Lymph Nodal Metastasis from Anal Cancer vol.13, pp.1, 2020, https://doi.org/10.1159/000505969
  5. Late Toxicities, Failure Patterns, Local Tumor Control, and Survival of Esophageal Squamous Cell Carcinoma Patients After Chemoradiotherapy With a Simultaneous Integrated Boost: A 5-Year Phase II Stud vol.11, pp.None, 2021, https://doi.org/10.3389/fonc.2021.738936
  6. Reducing variability among treatment machines using knowledge‐based planning for head and neck, pancreatic, and rectal cancer vol.22, pp.7, 2017, https://doi.org/10.1002/acm2.13316
  7. The Radiotherapy Role in the Multidisciplinary Management of Locally Advanced Vulvar Cancer: A Multidisciplinary VulCan Team Review vol.13, pp.22, 2017, https://doi.org/10.3390/cancers13225747